What is it about?
This case report demonstrates effectiveness of regorafenib, oral-multikinase inhibitor for hepatocellular carcinoma. Regorafenib was administered as second-line therapy to patients who showed resistance to first-line sorafenib treatment. The patient achieved unexpected long-term regression and complete metabolic response despite discontinuation of regorafenib due to side effects. It is known that multikinase inhibitor, unlike cytotoxic chemotherapy, results in disease stabilization rather than tumor shrinkage, so the probability of achieving complete cure is low. However, our patient achieved complete regression after regorafenib discontinuation. Regorafenib is thought to be able to affect tumor regression through immunomodulatory effects such as antitumor immunity enhancement and downregulation of immunosuppressive molecules as well as antiangiogenic effects.
Featured Image
Why is it important?
This case addresses the critical importance of recognizing effectiveness of regorafenib, multikinase inhibitor for complete regression of hepatocellular carcinoma.
Perspectives
We believe that this research publication presents a new perspective in hepatocellular carcinoma treatment.
Heewon Bae
Veterans Health Service Medical Center
Furthe researches on regorafenib are needed to understand other unknown mechanisms such as immunomodulation.
Taekyu Lim
VHS Medical Center, Seoul, South Korea
Read the Original
This page is a summary of: Long-term regression after discontinuation of regorafenib administered for sorafenib-refractory hepatocellular carcinoma, Liver Cancer, January 2023, Karger Publishers,
DOI: 10.1159/000529139.
You can read the full text:
Contributors
The following have contributed to this page
